Published in BMC Psychiatry on January 28, 2010
Determining engagement in services for high-need individuals with serious mental illness. Adm Policy Ment Health (2014) 0.90
Schizophrenia--time to commit to policy change. Schizophr Bull (2014) 0.86
The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy. Clinicoecon Outcomes Res (2013) 0.85
Global economic burden of schizophrenia: letter in response. Neuropsychiatr Dis Treat (2016) 0.83
Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders. BMC Psychiatry (2014) 0.80
The Cost of Relapse in Schizophrenia. Pharmacoeconomics (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull (1987) 51.07
Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry (2008) 4.93
Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull (1998) 4.01
The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry (2005) 3.92
Cost of relapse in schizophrenia. Schizophr Bull (1995) 3.04
Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care (2002) 2.68
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry (2006) 2.49
The global costs of schizophrenia. Schizophr Bull (2004) 2.44
Criminal victimization of persons with severe mental illness. Psychiatr Serv (1999) 2.40
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health (2006) 1.97
Extending Assertive Community Treatment to criminal justice settings: origins, current evidence, and future directions. Community Ment Health J (2007) 1.90
Cost of schizophrenia in England. J Ment Health Policy Econ (2007) 1.58
Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull (2004) 1.45
Assault experiences of 100 psychiatric inpatients: evidence of the need for routine inquiry. Am J Psychiatry (1987) 1.43
The costs of schizophrenia. J Clin Psychiatry (2007) 1.05
Involvement with the criminal justice system among new clients at outpatient mental health agencies. Psychiatr Serv (2005) 1.04
Crimes against discharged mental patients in board-and-care homes. Am J Psychiatry (1984) 1.03
Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc Psychiatry Psychiatr Epidemiol (1998) 1.01
Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics (2003) 0.98
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry (2004) 0.97
Legal system involvement and costs for persons in treatment for severe mental illness and substance use disorders. Psychiatr Serv (1999) 0.86
Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ (2008) 0.86
Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv (2003) 0.80
Chronic mental illness and the criminal justice system. Hosp Community Psychiatry (1989) 0.78
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med (2003) 4.04
The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry (2005) 3.92
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry (2006) 2.49
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med (2004) 2.24
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2002) 2.00
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health (2006) 1.97
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med (2004) 1.73
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol (2003) 1.70
Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. J Dev Behav Pediatr (2004) 1.63
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med (2005) 1.57
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry (2009) 1.53
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry (2011) 1.48
Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: pooled results from 10 phase 1 studies. J Clin Psychopharmacol (2012) 1.40
Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood) (2008) 1.40
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull (2007) 1.36
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry (2004) 1.23
Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes? J Child Adolesc Psychopharmacol (2006) 1.17
Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry (2008) 1.09
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol (2009) 1.05
Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res (2013) 1.04
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry (2005) 1.02
Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm (2009) 1.01
Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence (2008) 1.01
Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend (2008) 1.01
Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) (2006) 0.99
Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res (2007) 0.99
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry (2013) 0.98
Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry (2010) 0.98
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res (2006) 0.98
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics (2002) 0.96
Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res (2011) 0.95
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry (2009) 0.93
Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin (2010) 0.92
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol (2005) 0.92
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiatry (2008) 0.92
A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry (2006) 0.91
Persistence with biologic therapies in the Medicare coverage gap. Am J Manag Care (2011) 0.90
Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes (2009) 0.90
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res (2010) 0.89
Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia. J Clin Psychopharmacol (2007) 0.89
Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clinicoecon Outcomes Res (2011) 0.89
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry (2014) 0.89
Costs associated with attempted suicide among individuals with bipolar disorder. J Ment Health Policy Econ (2010) 0.88
Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Prefer Adherence (2007) 0.87
Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc (2009) 0.87
Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatr Serv (2011) 0.87
Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study. BMC Psychiatry (2012) 0.87
Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy? Chemother Res Pract (2010) 0.86
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry (2009) 0.85
Optimal thresholds of early response to atypical antipsychotics: application of signal detection methods. Schizophr Res (2009) 0.85
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia. Curr Med Res Opin (2007) 0.85
Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. Neuropsychiatr Dis Treat (2012) 0.85
Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull (2007) 0.85
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone. J Clin Psychiatry (2011) 0.85
Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res (2011) 0.84
Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs. Pharmacoeconomics (2004) 0.84
Development of a clinician questionnaire and patient interview to assess reasons for antipsychotic discontinuation. Psychiatry Res (2011) 0.84
Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci (2004) 0.84
Using U.S. Medicare records to evaluate the indirect health effects on spouses: a case study in Alzheimer's disease patients. BMC Health Serv Res (2014) 0.84
Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients. BMC Psychiatry (2009) 0.83
Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry (2011) 0.82
Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat (2009) 0.82
A provisional screening instrument for four common mental disorders in adult primary care patients. Psychosomatics (2011) 0.82
Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change. J Clin Psychiatry (2011) 0.82
The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial. BMC Psychiatry (2011) 0.81
Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective. J Med Econ (2011) 0.81
Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Prefer Adherence (2011) 0.81
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence (2010) 0.81
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia. Curr Med Res Opin (2008) 0.81
Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators. Pain Pract (2013) 0.81
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr Res (2011) 0.80
Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J Clin Psychiatry (2014) 0.80
PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients. Postgrad Med (2011) 0.79
Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy. Clinicoecon Outcomes Res (2011) 0.79
Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine. J Med Econ (2013) 0.79
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin (2010) 0.79
Costs of treating patients with schizophrenia who have illness-related crisis events. BMC Psychiatry (2008) 0.78
A short-term, multicenter, placebo-controlled, randomized withdrawal study of a metabotropic glutamate 2/3 receptor agonist using an electronic patient-reported outcome device in patients with schizophrenia. J Clin Psychopharmacol (2014) 0.78
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial. BMC Med Res Methodol (2012) 0.78
Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Res (2012) 0.78
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol (2007) 0.78
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol (2006) 0.77
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ann N Y Acad Sci (2004) 0.77
The 3-year clinical and functional course of schizophrenia among individuals with and without diabetes at study entry. Prim Care Companion J Clin Psychiatry (2007) 0.77